A Phase 3 Multicenter, Randomized, Double-blind Placebo-controlled Trial Evaluating Crofelemer for the Prophylaxis of Diarrhea in Adult Patients With Solid Tumors Receiving Targeted-cancer Therapies With or Without Standard Chemotherapy
Latest Information Update: 19 Mar 2025
At a glance
- Drugs Crofelemer (Primary)
- Indications Diarrhoea
- Focus Registrational; Therapeutic Use
- Acronyms OnTARGET
- Sponsors Jaguar Health; Napo Pharmaceuticals
Most Recent Events
- 26 Jul 2024 Status changed from active, no longer recruiting to completed.
- 21 Jun 2024 According to a Jaguar Health media release, company will report pivotal phase 3 OnTarget trial results for its cancer supportive care drug crofelemer on or before July 23, 2024.
- 11 Apr 2024 Planned End Date changed from 1 Apr 2024 to 1 Jun 2024.